Q301--Long -Term Specialized Reference Laboratory for Measurable Residual Disease (MRD) detection in hematologic malignancies - Base Plus 4 9/1/26-8/31/31

The Department of Veterans Affairs (VA), Network Contracting Office 20 (NCO 20), is conducting market research on behalf of the Portland VA Medical Center to identify potential contractors capable of providing reagents and consumables for laboratory tests for the VA medical facilities and clinics. The Portland VA Medical Center is comprised of: Portland VA Medical Center. Vancouver VA Medical Center. Astoria VA Clinic. Fairview VA Clinic. Hillsboro VA Clinic Lincoln City VA Clinic Loren R. Kaufman VA Clinic Newport VA Clinic Portland VA Clinic Robert D. Maxwell Department of Veterans Affairs Clinic Salem VA Clinic West Linn VA Clinic To be considered a responsive and potential source, interested parties shall provide a capabilities statement containing the following information: Business name, address, point of contact, phone number and email address. Business size, type, and SAM Unique Identifier Number Affirmation that the vendor is capable of performing in accordance with the attached Statement of Work. The vendor shall provide copies of government licenses appropriate to do the work described in the Statement of Work. Additionally, contractors can provide feedback on the attached Requirements Description, which may be considered if a solicitation is posted. Provide the requested information to Hector Gonzalez at hector.gonzalez1@va.gov before 10:00 am PST on July 10th 2026. All question must be submitted in writing, no telephonic inquiries will be accepted. This is a sources-sought notice only. The purpose of this notice is to obtain information regarding the availability and capability of verified sources to include qualified SDVOSB/VOSB to perform this potential requirement. Responses received will assist the Government in determining the appropriate acquisition strategy. The Government may or may not issue a solicitation as a result of this notice. There is no solicitation available at this time, and this is not a request for quotes. STATEMENT OF WORK (SOW) for Reference Laboratory Services for specialized testing for Measurable Residual Disease (MRD) detection in hematologic malignancies BACKGROUND The VA Portland Healthcare System (VHAPORHCS) Pathology & Laboratory Medicine Service Department requires continued access to specialized testing for Measurable Residual Disease (MRD) detection in hematologic malignancies. MRD is a powerful diagnostic and prognostic tool that quantifies the presence of residual cancer cells during and after treatment in patients with multiple myeloma, B-cell acute lymphoblastic leukemia (B-ALL), and chronic lymphocytic leukemia (CLL). The contractor shall provide MRD testing of an FDA-cleared, next generation sequencing (NGS)-based assay — for blood and bone marrow samples from patients diagnosed with multiple myeloma (MM), chronic lymphocytic leukemia (CLL), and B-cell acute lymphoblastic leukemia (B-ALL). Testing shall be performed at the contractor’s CLIA-certified (requirement) and CAP-accredited (or equivalent; requirement) reference laboratory and include full interpretation and reporting of results to VHAPORHCS clinicians. This full-service Reference Laboratory contract will provide services required for specimen testing, interpretation, testing supplies, and customer service. This requirement will ensure accurate and timely test results are made available to healthcare providers which will ensure high quality healthcare is provided to the Veterans at the VA Portland Health Care System. SCOPE The objective of this agreement is to provide VHAPORHCS with access to FDA-cleared and clinically validated MRD testing to support direct patient care within the Hematology/Oncology and Pathology and Laboratory Medicine Services (PALMS), ensuring accurate disease monitoring and outcome assessment for veterans undergoing cancer therapy. The contractor shall: Provide MRD testing for the following specimen and disease types: Bone marrow aspirate or peripheral blood for: Multiple Myeloma (MM) Chronic Lymphocytic Leukemia (CLL) B-cell Acute Lymphoblastic Leukemia (B-ALL) FFPE Bone Marrow tissue (as applicable) Please see Attachment A to this Statement of Work (SOW) for the test and quantities required by VAPORHCS. Perform testing within the contractor’s CLIA-certified, CAP-accredited (or equivalent) laboratory using FDA-cleared protocols. Provide average turnaround time shall be (6) business days from receipt of specimen. Provide secure electronic results via a vendor-managed portal and fax reports directly to designated VA clinicians. Maintain a customer-accessible results portal for tracking orders and retrieving historical patient data. Provide technical support for order management and result interpretation. Ensure all testing is performed using validated instruments, reagents, and methodologies per FDA clearance and CLIA/CAP (or equivalent) standards. The Reference Laboratory shall also provide the following support services: supplies, customer service, reporting services, and verification of certification. Provide all necessary supplies as defined in the laboratory user manual, to include, but not limited to the following: Requisition forms or agreed computer ordering system Specimen containers & collection kits Specimen requirements for specimen collection & specimen processing Methodologies and reference ranges Expected turn-around times All forms, including authorization of consent for genetic testing, informed consent, and chain of custody. The VAPORHCS requires that the Reference laboratory provide technical and consultative support as it relates to any results provided by the vendor. The vendor shall identify on Attachment A, whether the testing is performed in-house or sent out/referred to an alternate lab, not owned by the vendor. Clinical Application and Importance: The MRD assay is clinically essential for identifying and quant…